List of Cleviprex drug patents

Cleviprex is owned by Chiesi.

Cleviprex contains Clevidipine.

Cleviprex has a total of 3 drug patents out of which 0 drug patents have expired.

Cleviprex was authorised for market use on 01 August, 2008.

Cleviprex is available in emulsion;intravenous dosage forms.

The generics of Cleviprex are possible to be released after 10 October, 2031.

CLEVIPREX's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103490 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(8 years from now)

US10010537 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(8 years from now)

US8658676 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(8 years from now)

Do you want to check out CLEVIPREX patents from before 2022?

Drugs and Companies using CLEVIDIPINE ingredient

Market Authorisation Date: 01 August, 2008

Treatment: NA

Dosage: EMULSION;INTRAVENOUS

How can I launch a generic of CLEVIPREX before it's patent expiration?
More Information on Dosage

CLEVIPREX family patents

6

United States

3

Japan

2

Mexico

2

Korea, Republic of

1

Canada

1

Brazil

1

China

1

Australia

1

New Zealand

EA

1

EA

1

Denmark

1

Portugal

1

Hungary

1

Spain

1

Poland

1

Hong Kong

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in